ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
ANDREW FENSOME, a principal research scientist at Wyeth, will receive the 2007 David W. Robertson Award for Excellence in Medicinal Chemistry during the ACS fall national meeting in Boston in August. Supported by Pfizer and presented by the ACS Division of Medicinal Chemistry, the award recognizes seminal contributions by young scientists to medicinal chemistry and is in memory of Robertson, a medicinal chemist.
Fensome has played a leading role in nuclear hormone receptor research at Wyeth. His work on the development of nonsteroidal oral contraceptive agents has resulted in seven drug candidates that have advanced as developmental compounds, with PRA-989 (tanaproget) completing Phase II clinical studies as an oral contraceptive. Improved variants of tanaproget are now advancing into clinical studies.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X